Mast cells play important roles in innate immunity through their activation via toll-like receptors (TLRs) but also contribute to neuroimmunological responses and inflammation through their activation by the neuropeptide substance P (SP) via Ga ilo proteins. This study aims to compare the effects of the TLR2 agonists peptidoglycan (PGN) and tripalmitoyl-S-glycero-Cys-(Lys)4 (Pam3CSK4) on SP-induced human mast cell activation. The human mast cell line LAD2 was employed and mast cell activation was determined by assays of p-hexosaminidase, IL-8 and intracellular calcium. TLR2 agonists did not cause degranulation, but induced the release oflL-8. Pretreatment ofPGN and Pam3CSK4 inhibited SP induced degranulation but only Pam3CSK4 blocked SP induced calcium mobilization. SP-induced IL-8 release was synergistically enhanced by PGN but abolished by Pam3CSK4. Studies with inhibitors of key enzymes implicated in mast cell signaling revealed that synergistic release oflL-8 induced by PGN and SP involved calcineurin, ERK, NF-KB and PI3K signaling cascades whereas Pam3CSK4 inhibited SP induced mast cell activation by interfering with the interaction between SP and Ga ilo proteins. These findings suggest that activation of human mast cells can be differentially modified by TLR2 agonists via distinct signaling pathways through facilitating formation of different TLR2 heterodimers with other TLRs.
Mast cells play important roles in innate immunity through their activation via toll-like receptors (TLRs) but also contribute to neuroimmunological responses and inflammation through their activation by the neuropeptide substance P (SP) via Ga ilo proteins. This study aims to compare the effects of the TLR2 agonists peptidoglycan (PGN) and tripalmitoyl-S-glycero-Cys-(Lys)4 (Pam3CSK4) on SP-induced human mast cell activation. The human mast cell line LAD2 was employed and mast cell activation was determined by assays of p-hexosaminidase, IL-8 and intracellular calcium. TLR2 agonists did not cause degranulation, but induced the release oflL-8. Pretreatment ofPGN and Pam3CSK4 inhibited SP induced degranulation but only Pam3CSK4 blocked SP induced calcium mobilization. SP-induced IL-8 release was synergistically enhanced by PGN but abolished by Pam3CSK4. Studies with inhibitors of key enzymes implicated in mast cell signaling revealed that synergistic release oflL-8 induced by PGN and SP involved calcineurin, ERK, NF-KB and PI3K signaling cascades whereas Pam3CSK4 inhibited SP induced mast cell activation by interfering with the interaction between SP and Ga ilo proteins. These findings suggest that activation of human mast cells can be differentially modified by TLR2 agonists via distinct signaling pathways through facilitating formation of different TLR2 heterodimers with other TLRs.
Mast cells are tissue resident immune effector cells which could be activated through cell surface IgE receptors (FctRI) (1). Beyond their roles in allergic diseases, mast cells are now appreciated to involve extensively in the pathogenesis of diverse diseases associated with chronic inflammation through IgE receptor independent mechanisms. The neuropeptide substance P (SP) released from sensory nerve endings is a key mediator of neurogenic inflammation (2) . SP directly stimulates tissue mast cells through an FctRI independent peptidergic pathway that is shared by a group of polycationic compounds (3) . The exact mechanism of the peptidergic pathway is not well defined, but the involvement ofpertussis toxin (PTX)-sensitive G proteins that lead to intracellular calcium increase as well as the activation of phospholipase Cp (PLCP) and phosphatidylinositol 3-kinase (PI3K) have long been demonstrated (4, 5) . Similar to immunologic activation with antigens, mast cells respond to SP by degranulation and secretion of de novo synthesized mediators (3, 5, 6) .
The toll-like receptor (TLR) family belongs to the pattern-recognition molecules/receptors, which is at the center of the detection mechanisms for the innate immune system. Expression of TLRs on mast cells provides another FCtRI independent activation mechanism that enhances the capacity of mast cells to defend against a wide variety of pathogens. TLRs share a common signaling pathway following dimerization of TLRs by activating ligands (7) . Initial recruitment of the adaptor molecule myeloid differentiation primary-response protein 88 (MyD88) and subsequently IL-l R-associated protein kinases (IRAKs) ultimately leads to the activation of nuclear factor kappa B (NF-KB) (7) . Among the ten identified TLRs in humans, TLR2 forms heterodimer with TLRI or TLR6, and is associated with the recognition of Gram-positive bacteria, mycoplasma, fungi, and viruses (8, 9) .
Peptidoglycan (PGN) and tripalmitoyl-Sglycero-Cys-(Lys)4 (Pam3CSK4) are two TLR2 ligands that have been widely used to investigate the effects of TLR2 on mast cell activation. While PGN is a primary cell wall component of Grampositive bacteria which activates TLR2 and TLR6 heterodimer (10, 11) , Pam3CSK4 is a synthetic tripalmitoylated lipopeptide which binds to TLR2 and TLRI heterodimer (12) . Although many studies drew their conclusions regarding TLR2 activities in biological systems by employing either PGN or Pam3CSK4 as a single prototype TLR2 activator, these distinct TLR2 ligands have been shown to induce differential mediator generation and release from human mast cells (13) .
During the course of innate immune response triggered by bacterial infections, mast cells are likely to be exposed to and stimulated by TLR2 ligands associated with the invading microorganisms and SP released from nerve endings in the infected tissues simultaneously. However, the interaction between these two Fe RI independent mechanisms on mast E cell activation has not been widely investigated. In the current study, we hypothesized that SP-induced activation of human mast cells would be modified by TLR2 ligands. The two widely accepted TLR2 ligands PGN and Pam3CSK4 were employed to further investigate whether there are differences between the effects of respectively TLR2/TLR6 and TLR2/TLRI heterodimers on human mast cell activation.
MATERIALS AND METHODS

Human mast cell culture
The Laboratory of Allergic Disease 2 (LAD2) human mast cells were kindly provided by A. Kirshenbaum and D. Metcalfe (NIH, USA) (14) . Cells were maintained in StemPro-34 medium supplemented with l Oml/I StemPro nutrient supplement, I: I00 penicillin-streptomycin, 2mmolll L-glutamine, 100ng/ml human stem cell factor, and 50ng/ml interleukin-6 in an atmosphere containing 5% CO 2 at 37°C.The culture medium was replaced every 2 weeks and the cells were kept at a density of 2 x 10 5 cells/m\.
Chemical reagents
Peptidoglycan (PGN) from S. aureus, SP, mouse antihuman immunoglobulin E antibody (s-chain specific, antiIgE) and benzalkonium chloride (BAC) were purchased from Sigma. Pam3CSK4 was purchased from Invivogen. SP600125, SB203580, PD98059, ciclosporin and Bayll-7821 were from Tocris. Wortmannin was from Cayman. PTX was from Calbiochem. When chemicals were dissolved in DMSO, the final concentration of DMSO did not alter the normal response of LAD2 cells.
Degranulation assaỹ
-hexosaminidase (~-hex) is an enzyme contained in the cytoplasmic granules of mast cells and the degree of release of this enzyme into the supernatant provides an indication of the degranulation process which immediately occurs following mast cell activation. LAD2 cells were respectively incubated with different stimuli for 30 min and~-hex release was measured.~-hex in supernatants and cell Iysates was determined by use of a colorimetric assay in which release ofp-nitrophenol from 4-nitrophenyl N-acetyl-~-D-glucosaminide was measured (15) . The absorbance was measured at 405 nm by using a multiplate reader. 605 nm reading was taken as a reference. The percentage of~-hex release was calculated as the percentage of the total~-hex content. All results were corrected for spontaneous~-hex release that was less than 5%.
IL-8 measurement
LAD2 cells were pre-incubated with various inhibitors for the corresponding time periods prior to incubation with different stimuli for 24 h to allow synthesis and release ofIL-8. The release ofIL-8 in the supernatants was measured by ELISA assay (BD Biosciences) according to the manufacturer's instructions. All results were corrected for spontaneous IL-8 release that was less than 22 pg/l 0 6 cells.
Intracellular CaJ+ mobilization assay
LA02 cells were loaded with 2 JlM rura-2 AM (Invitrogen) for 30 min at 37°C. The cells were washed three times with HEPES buffer with human albumin and resuspended in it and then challenged with different stimuli. Fura-2-loaded mast cells were viewed with an Olympus inverted IX51 microscope. They were captured with a CCD camera at every 10 second interval. Fluorescence images were obtained at wavelengths of 340 and 380 nm with an emission wavelength of 510 nm. The fluorescence ratio of 340 to 380 nm was measured and analyzed. F/F o was the fluorescence ratio of time-point X divided by the ratio of time-point zero.
Statistical analysis
Statistical significance was determined by student's t-test, one-way or two-way ANOVA. Differences were considered significant at a P value of less than 0.05. All data are expressed as means ± standard error of means (SEMs).
RESULTS
TLR2 ligands suppressed LAD2 cell degranulation induced by substance P
PGN and Pam3CSK4 did not induce significant release of p-hex on their own (Fig. 1A, B) while SP induced the release of around 48% of total p-hex following a 30 min incubation with LAD2 cells. When added to LAD2 cells simultaneously with SP, PGN did not suppress SP induced p-hex release while Pam3CSK4 was only effective at the highest concentration of 20 ug/ml tested. In contrast, dosedependent inhibition of SP-induced p-hex release from LAD2 cells was observed with both TLR2 agonists when LAD2 cells were activated after pre-incubation with the TLR2 agonists for 24 h. Pam3CSK4 was more potent as total inhibition was observed at 10 ug/ml of Pam3CSK4 but only around 50% inhibition was achieved with PGN at 100 ug/rnl (Fig. lA, B ). 
TLR2 ligands differentially regulated substance P-induced IL-8 release from LAD2 cells
TLR2 ligands differentially regulate substance P-induced intracellular calcium increase in LAD2 cells
An increase in concentration of cytosolic calcium is essential both for degranulation and for release of de novo synthesized mediators in mast cells (1).
SP induced a rapid increase of [Ca"'] with peak elevation at around 3 min after activation that was followed by gradual reduction over the observation period. Pam3CSK4 induced a much lower but sustained level of [Ca2+l that was significant at around 3 min after activation while PGN did not cause intracellular calcium increase ( Fig. 2A, B) . When added simultaneously with SP, PGN enhanced SP-induced calcium increase ( Fig. 2A) while Pam3CSK4 reduced SP-induced calcium increase, but was still stronger than that of Pam3CSK4 alone (Fig. 2B) . Following 24-h pre-incubation, PGN did not affect but Pam3CSK4 totally abolished SPinduced calcium increase (Fig. 2C, D) .
Synergistic release of IL-8 induced by concomitant activation of LAD2 cells by substance P and PGN was inhibited by blockers of calcineurin, PI3K and NF-KB
In this series of experiments, LAD2 cells were pre-incubated with an inhibitor for 30 min before the addition of various mast cells activators. Activation of calcineurin induced by [Ca"]. increase contributes to the release of cytokines from SP stimulated mast cells (16) . As illustrated in Fig. 3A , IL-8 release induced by Pam3CSK4, SP and their combination were significantly blocked by the specific inhibitor of calcineurin, ciclosporin (2 ug/ml), In contrast, ciclosporin did not change PGN induced IL-8 release from LAD2 cells (Fig. 3A) but was capable of reducing the synergistic release of IL-8 induced by PGN together with SP by 50% (Fig. 3A) .
NF-KB is generally believed to be involved in the release of cytokines and chemokines induced by agents that activate TLRs and PTX-sensitive G./ (Fig. 3B) . Only the synergistic release of IL-8 induced by PGN combined with SP was significantly inhibited by Bay 11-7821 (Fig. 3B) . PI3K is well known to participate in human mast cells activity in term of degranulation and release of de novo synthesized mediators in response to various cell surface receptors (17) . Direct evidence for the requirement of PI3K in TLR2 signaling activation was shown by Arbibe et al. (18) . The PI3K inhibitor wortmannin (0.5 11M) inhibited IL-8 release induced by PGN, SP and their combination (Fig. 3C) . However, this inhibitor failed to demonstrate any effect on IL-8 release induced by Pam3CSK4 alone or in combination with SP (Fig. 3C) .
Involvement of MAPKs in TLR2 and substance P induced mast cell activation
TLR2 ligands and SP both had been reported to induce the tyrosine phosphorylation of MAPKs, which are important signaling molecules for the production of a wide variety of cytokines and chemokines in mast cells (5, 19) . The ERK inhibitor PD98059 (l 0~M) significantly inhibited IL-8 release from LAD2 cells induced separately by PGN, Pam3CSK4, SP and the combinations of SP with either TLR2 agonist (Fig. 4A) . The JNK inhibitor SP600125 (20~M) only inhibited PGNinduced release of IL-8 from LAD2 cells, but did not inhibit the synergistic release of IL-8 induced by co-stimulation of PGN with SP, nor did it change the IL-8 release induced by Pam3CSK4, SP or their combination (Fig. 4B) . The p38 inhibitor SB203580 (to~M) did not influence the release ofIL-8 induced by PGN, Pam3CSK4, SP or the combination of SP with either of two TLR2 ligands (Fig. 4C ).
The mast cell activating actions ofsubstance P and Pam3CSK4 were inhibited by PTX but differentially modulated by benzalkonium chloride
We next investigated the involvement of PTXsensitive Gu i / o proteins as they have been implicated in the mast cell activating pathways of both SP and TLR2 (6, 20) . Anti-IgE induced IL-8 release was included as a negative control as Gu i through FccRI (I). Pre-incubation with PTX for 2 h prior to activation significantly reduced IL-8 release induced by Pam3CSK4 and SP but not that induced by PGN and anti-IgE (Fig. 5A ). In addition, pretreatment of PTX significantly inhibited calcium increase induced by SP and Pam3CSK4 (Fig. 5B, C) . Since PTX inhibits both Gn and Go protein, , 0 BAC was employed to identify which of these subtypes was involved as it inhibits Gu i , but potentiates Guo (21, 22) . SP-induced~-hex release from LAD2 cells was inhibited by pre-incubation with BAC for 10 min in a dose-dependent manner (Fig. 6A) , suggesting the involvement of only GU i protein. However, SP-induced IL-8 release was significantly enhanced by BAC at Sug/ml followed by the loss of the enhanced release at I0 ug/rnl, suggesting the involvement of both Guo and GU j proteins with the former being more sensitive to the lower concentration of BAC (Fig. 6B) . The level of IL-8 release was thus determined by the balance between the potentiation of Guo and the inhibition of GU j protein by BAC in LAD2 cells. The lack of significant modulation ofPGN-induced IL-8 release by BAC suggested that G proteins in general do not playa significant role in TLR2/TLR6-induced mast cell activation (Fig. 6C) . In contrast, IL-8 release induced by Pam3CSK4 was significantly enhanced by BAC at both 5 and l Oug/rnl, indicating that Pam3CSK4 activated predominantly the Gao protein in LAD2 cells (Fig. 6D ).
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DISCUSSION
Substance P is implicated in various inflammatory reactions by activating mast cells through the FcERI receptor independent peptidergic pathways. Synergistic release of IL-8 and TNF-a through upregulation of TLR2 expression was observed in a previous study where LAD2 cells were pre-incubated with SP for 24 h prior to being challenged with lipoteichoic acid or Pam3CSK4 (23) . In contrast, our data showed that the two commonly employed TLR2 agonists, PGN and Pam3CSK4, differentially modulated SP-induced human mast cell activation via distinct mechanisms when the cells were challenged with SP together or after 24-h pre-incubation with the TLR2 ligands. This is the first study reporting the differential modulation of SP-induced mast cell activation by TLR2 ligands. Since PGN and Pam3CSK4 are known to facilitate the activation of TLR2/TLR6 and TLR2/ TLRI heterodimers respectively (24), our results further suggests that SP-induced inflammatory reactions through mast cells can be enhanced or suppressed depending on the nature of the invading microorganisms.
Pre-incubation with PGN and Pam3CSK4 for 24 h both suppressed SP-induced degranulation with Pam3CSK4 being more potent. Degranulation in mast cells involves two key events, the calcium-independent and microtubule-dependent translocation of granules to the plasma membrane and the calcium-dependent membrane fusion and exocytosis (25, 26) . Although increase in [Ca"], is required for the full activation of mast cells but only Pam3CSK4 was effective in reducing SP-induced [Ca"] increase while PGN was not effective. Since Pam3CSK4 was capable of inducing sustained low level of [Ca"]. increase which was not adequate to trigger degranulation, Pam3CSK4 might suppress the activation mechanisms employed by SP through competition for the same sources of calcium. On the other hand, PGN may initiate calcium-independent inhibitory mechanisms to suppress the degranulation induced by SP. Although the predominant effect of PGN is suppression of SP-induced degranulation, it is interesting to note that SP-induced calcium increase and~-hex release were slightly enhanced by simultaneous activation ofLAD2 cells with PGN. The enhancement was not statistically significant but the results suggested that there was potential cross-talk between TLR2/TLR6 heterodimer and the peptidergic pathway which might contribute to the synergistic synthesis of IL-8 as observed in this study.
The employment of inhibitors of enzymes in various signaling pathways involved in cytokine synthesis in mast cells revealed further differences in the mast cell modulatory actions of PGN and Pam3CSK4. The release of IL-8 induced by PGN required the activation of JNK, ERK, and PI3K signaling cascades while that induced by Pam3CSK4 required only ERK and calcineurin signaling systems. In addition to the previously reported involvement of PI3K (6), we further demonstrated that ERK and calcineurin contributed to SP-induced IL-8 release. Furthermore, the failure of Bay 11-7821 to reduce IL-8 release induced by PGN or Pam3CSK4 supported previous studies which demonstrated LAD2 cells required more of MAPKs than NF-KB for chemokines secretion (20, 23) . In addition to demonstrating that different signaling pathways are required by PGN and Pam3CSK4 in human mast cells, our results provide further evidence supporting that TLR2/TLR6 and TLR2/TLRI heterodimers would activate different signaling mechanisms as previously illustrated in macrophages (27) .
The different signaling pathways induced by PGN and Pam3CSK4 also resulted in the opposite modulatory effect on human mast cell activation in response to SP. In addition to the inhibitors for calcineurin, ERK, and PI3K which reduced IL-8 release induced separately by PGN or SP, synergistic release of IL-8 induced by PGN and SP was also reduced significantly by the inhibitor ofNF-KB. The failure of the JNK inhibitor, which was effective in reducing PGN-induced IL-8, to reduce the enhanced IL-8 release suggested that ERK is the major MAPK contributing to the synergistic action. The inhibitory action of Bayll-7821 suggested that NF-KB was synergistically activated when LAD2 cells were simultaneously activated through the TLR2/TLR6 heterodimer and the peptidergic pathway which may be due to the enhanced activation of the PI3K1 Akt signaling cascade and ERK since both are wellknown upstream targets for NF-KB activation (1). Enhanced activation of the P13K1MAPKs signal, especially through the distinct MyD88-dependent (PGN-mediated) and calcium-dependent signals (SPmediated) may be sufficient to trigger the activation of the NF-KB system.
The level of IL-8 release following incubation with SP and Pam3CSK4 together remained at the level induced by Pam3CSK4 alone, suggesting that Pam3CSK4 directly interfered with the interaction of SP with LAD2 cells. Pam3CSK4 and SP seem to mediate similar signaling pathways as illustrated by the similar modulatory actions of inhibitors of the various signaling molecules with the exception of wortmannin which inhibited only IL-8 release induced by SP. Meanwhile, release of IL-8 induced by Pam3CSK4 with SP was not inhibited by wortmannin, indicating that the effect ofPam3CSK4 dominated that of SP. Together with the Pam3CSK4-induced calcium increase and the inhibition of SPinduced degranulation, all these observations with IL-8 release suggest that Pam3CSK4 may occupy or inhibit a critical initial signaling molecule which is required for SP-induced human mast cell activation.
The inhibitory action of PTX on Pam3CSK4-induced calcium increase and IL-8 release suggests this crucial molecule to be GU ilo proteins. Our study with BAC further identified that Guo protein contributed to the release of de novo synthesized mediators while GU i protein contributed to both degranulation and de novo synthesized mediator release in LAD2 cells. The sustained potentiation of Pam3CSK4-induced IL-8 release by BAC at a concentration suppressing degranulation suggested that Pam3CSK4 activated predominantly Guo protein for the synthesis of this chemokine. Absence of degranulation induced by Pam3CSK4 may be due to its lower efficacy to stimulate the GU i protein in LAD2 cells. The failure of PTX to inhibit PGNinduced IL-8 release suggested that the activation of GU ilo proteins is not a common mechanism shared by TLR2 agonists. We thus hypothesize that Pam3CSK4 inhibited SP-mediated responses in LAD2 cells by occupying the binding site for SP on GU ilo proteins possibly by a mechanism mediated through TLR2/ TLRI heterodimers, as previously suggested by Zaidi, et al. (20) .
In summary, our results support previous observations that mast cells have a complicated and flexible regulatory mechanism to equip themselves specifically for different inflammatory situations to produce either positive or negative immunomodulatory functions (28) . Activation of TLR2/TLR6 heterodimers, such as that induced by PGN, amplifies neurogenic inflammation generated by SP-induced mast cell cytokine release. In contrast, activation of TLR2/TLRI heterodimer, such as that induced by Pam3CSK4, limits neurogenic inflammation induced by SP through preventing activation of mast cells by this neuropeptide. Depending on the type of TLR2 heterodimer activated by a microorganism, microbial infection may exaggerate or reduce inflammatory disorders that involve SP-induced mast cell activation such as asthma, rhinitis, irritable bowel diseases and cystitis. Although studies with inhibitors of signaling molecules provide a general outline of the possible signaling pathways involved, further confirmation with molecular studies will be required to reveal the detail mechanisms.
